- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
- 14 Feb 20 EFFECT Notice of effectiveness
- 13 Feb 20 POS AM Prospectus update (post-effective amendment)
- 11 Feb 20 POS AM Prospectus update (post-effective amendment)
- 22 Jan 20 POS AM Prospectus update (post-effective amendment)
- 2 Jan 20 EFFECT Notice of effectiveness
- 24 Dec 19 POS AM Prospectus update (post-effective amendment)
- 16 Dec 19 AW Withdrawal of amendment
- 9 Dec 19 POS AM Prospectus update (post-effective amendment)
- 14 Nov 19 424B3 Prospectus supplement
- 13 Nov 19 424B4 Prospectus supplement with pricing info
- 29 Oct 19 EFFECT Notice of effectiveness
-
22 Oct 19 S-1/A IPO registration (amended)
EXHIBIT 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
As independent registered public accountants, we hereby consent to the inclusion in this Registration Statement No. 333-231951 on Form S-1/A of our report dated March 14, 2019, relating to the consolidated financial statements of Emerald Bioscience, Inc., formerly known as Nemus Bioscience, Inc., and its subsidiary (which report includes an explanatory paragraph relating to the uncertainty of the Company’s ability to continue as a going concern), appearing in the December 31, 2018 Annual Report on Form 10-K of Emerald Bioscience, Inc. for the years ended December 31, 2018 and 2017, and to the reference to us under the heading “Experts” in this Registration Statement.
/s/ Mayer Hoffman McCann P.C.
Irvine, California
October 22, 2019